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Background: The selection of developmentally competent human gametes may increase the efficiency of assisted
reproduction. Spermatozoa and oocytes are usually assessed according to morphological criteria. Oocyte
morphology can be affected by the age, genetic characteristics, and factors related to controlled ovarian
stimulation. However, there is a lack of evidence in the literature concerning the effect of gonadotropin-releasing
hormone (GnRH) analogues, either agonists or antagonists, on oocyte morphology. The aim of this randomized
study was to investigate whether the prevalence of oocyte dysmorphism is influenced by the type of pituitary
suppression used in ovarian stimulation.
Methods: A total of 64 patients in the first intracytoplasmic sperm injection (ICSI) cycle were prospectively
randomized to receive treatment with either a GnRH agonist with a long-term protocol (n: 32) or a GnRH antagonist
with a multi-dose protocol (n: 32). Before being subjected to ICSI, the oocytes at metaphase II from both groups
were morphologically analyzed under an inverted light microscope at 400x magnification. The oocytes were
classified as follows: normal or with cytoplasmic dysmorphism, extracytoplasmic dysmorphism, or both. The number
of dysmorphic oocytes per total number of oocytes was analyzed.
Results: Out of a total of 681 oocytes, 189 (27.8 %) were morphologically normal, 220 (32.3 %) showed cytoplasmic
dysmorphism, 124 (18.2%) showed extracytoplasmic alterations, and 148 (21.7%) exhibited both types of
dysmorphism. No significant difference in oocyte dysmorphism was observed between the agonist- and
antagonist-treated groups (P> 0.05). Analysis for each dysmorphism revealed that the most common conditions
were alterations in polar body shape (31.3%) and the presence of diffuse cytoplasmic granulations (22.8%), refractile
bodies (18.5%) and central cytoplasmic granulations (13.6%). There was no significant difference among individual
oocyte dysmorphisms in the agonist- and antagonist-treated groups (P> 0.05).
Conclusions: Our randomized data indicate that in terms of the quality of oocyte morphology, there is no
difference between the antagonist multi-dose protocol and the long-term agonist protocol. If a GnRH analogue
used for pituitary suppression in IVF cycles influences the prevalence of oocyte dysmorphisms, there does not
appear to be a difference between the use of an agonist as opposed to an antagonist.
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In assisted reproduction, the selection of sperm, oocytes,
and embryos to achieve better clinical results are import-
ant tasks for the embryologist. This goal has particular
relevance when religious, ethical, or legal considerations
limit embryo selection after fertilization. The morpho-
logical evaluation of oocytes, although subjective, is still
the standard criterion to help identify the cells with the
greatest potential for development. The denudation step
not only allows for the evaluation of oocyte maturity by
identifying the first polar body but also allows for mor-
phological assessment of the zona pellucida, perivitelline
space, and cytoplasm [1]. Oocyte dysmorphisms may
occur due to age, genetic changes, and factors related to
the treatment itself, including the ovarian stimulation
and the hormonal environment to which the oocyte is
exposed [2-4].
The first therapeutic uses of in vitro fertilization (IVF)
were performed in natural cycles without ovarian stimu-
lation. However, there is currently a consensus that bet-
ter results are obtained with the induction of ovulation.
Thus, different protocols are being developed, many of
which rely primarily on the administration of gonadotro-
pins to induce multifollicular development, thus increas-
ing the number of available oocytes and thereby the
number of developing embryos to be selected and trans-
ferred. However, the induction of ovulation might induce
a premature surge in luteinizing hormone (LH), which
would cause premature luteinization or ovulation and
thereby prevent the collection of oocytes [5-9].
Both agonist and antagonist analogues of the
gonadotropin-releasing hormone (GnRH) play an import-
ant role in reducing the incidence of premature LH surges
by reversibly blocking the secretion of pituitary gonadotro-
pins. It is estimated that without the use of GnRH analo-
gues, a surge in LH occurs after approximately 20% of all
IVF cycles/intracytoplasmic sperm injections (ICSI) [10,11].
As a result, the frequency of cancelled assisted conception
cycles has decreased and pregnancy rates have increased.
GnRH agonists (GnRH-a) have been used in assisted
reproduction treatments since the 1980s. They suppress
the release of gonadotropins, including follicle-stimulating
hormone (FSH) and LH, by desensitizing pituitary recep-
tors, a phenomenon called “down-regulation” [8,12]. GnRH
antagonists (GnRH-ant) have only recently (since the late
1990s) been used as part of the therapeutic arsenal in the
field of assisted reproduction [13]. They act by directly
binding the GnRH receptors and block them in a competi-
tive manner [8]. Thus, GnRH-ant cause an immediate,
reversible, and rapid suppression of gonadotropin release
[6,8,12,14].
Although it is accompanied by some disadvantages,
GnRH-a have become well accepted in clinical practice,
and their use is associated with an increase in the rate ofpregnancy [15]. The development of GnRH-ant capable of
blocking the pituitary receptors offered a new therapeutic
option. Comparative studies between the two analogues
have suggested that the use of antagonists is associated
with a shorter duration of the ovulatory stimulus and a
decreased incidence of ovarian hyperstimulation syn-
drome; however, the rates of pregnancy and live birth do
not appear to be significantly affected, depending on the
type of GnRH analogue used [15-20]. Takahashi et al. [21]
found that the use of a GnRH-ant in controlled ovarian
hyperstimulation improves the outcome of pregnancy in
patients who have experienced several failed IVF/ICSI
cycles under a GnRH-a protocol, most likely due to an im-
provement in the quality of the blastocysts generated.
However, GnRH-a has applications in assisted reproduct-
ive technology cycles other than the down-regulation of pi-
tuitary receptors [15,22,23].
Although the human ovary expresses GnRH receptors,
the mechanism of the action of GnRH on the ovary
remains controversial and is not completely understood.
Thus, when GnRH analogues are used in IVF cycles,
their mechanism of action on the oocytes is unknown.
GnRH receptors are found in the luteal cells and granu-
losa cells of the antral follicles but not in primordial and
pre-antral follicles [24,25]. The correlation between the
expression of GnRH receptors and the stage of follicular
development suggests a direct influence of GnRH on fol-
liculogenesis and oocyte development. Unfortunately,
there are only a few studies on the possible action of
GnRH analogues on oocyte phenotype [1,4,26]. Those
results that have been published are often contradictory.
To better understand the effects of GnRH analogues on
the ovaries, the objective of this prospective, randomized
study was to evaluate whether the prevalence of oocyte dys-
morphism is influenced by the type of pituitary suppression
(GnRH-a or GnRH-ant) used in ovarian stimulation.
Methods
Participants
This prospective study was conducted on 64 women dur-
ing the first ICSI cycle at the Center for Human
Reproduction Professor Franco Junior. The inclusion cri-
teria were as follows: age ≤37 years, first IVF/ICSI cycle,
BMI <30 kg/m2, regular menses, and both ovaries present.
The exclusion criteria were as follows: polycystic ovarian
syndrome, severe endometriosis, ovarian cysts as assessed
by transvaginal ultrasound, and basal FSH ≥10 IU/ml.
Written consent was obtained from all the patients, and
the study was performed according to the norms of the
institutional ethics committee.
Randomization
A double randomization process was used. First, a
computer-generated table (first randomization) indicated
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ant) was assigned. Then, lots were drawn (second
randomization) to determine to which case that specific pa-
tient would correspond (i.e., case #1 or case #30). One
nurse, blinded to subject identities, performed all the lot
draws. In this manner, each patient was randomly allocated
to one of two groups:
1. GnRH-a group (n= 32): long-term GnRH agonist
(leuprolide acetate, LupronW, Abbott, Brazil) protocol
2. GnRH-ant group (n = 32): multi-dose GnRH




Pituitary down-regulation began during the luteal phase of
the previous menstrual cycle with the GnRH-a leuprolide
acetate (LupronW) at a dose of 1 mg/day for 14 days. The
ovaries were then stimulated with a fixed dose of 150 to
225 IU recombinant FSH (rFSH; Gonal FW; Serono) and
75 IU/day recombinant LH (rLH; LuverisW; Serono) for a
period of 7 days. On day 8 of ovarian stimulation, follicular
development was monitored by transvaginal ultrasound at
7 MHz (Medison Digital Color MT; Medison Co. Ltd.,
Seoul, Korea). The rFSH dose was adapted according to the
ovarian response, and rLH supplementation was increased
to 150 IU/day when one or more follicles measuring
≥10 mm in diameter were found.
GnRH-ant protocol
On Day 3 of the cycle, ovarian stimulation was induced
with a fixed dose of 150 to 225 IU rFSH and 75 IU/day rLH
for a period of 5 days. On day 8 of the menstrual cycle (day
6 of ovarian stimulation), follicular development was moni-
tored by transvaginal ultrasound at 7 MHz. The rFSH dose
was adapted according to the ovarian response, and rLH
supplementation was increased to 150 IU/day when one or
more follicles measuring ≥10 mm in diameter were found.
The GnRH-ant cetrorelix (CetrotideW) was started at a dose
of 0.25 mg/day s.c. when at least one follicle of ≥14 mm
was observed by ultrasound.
To induce the final oocyte maturation in both groups
(GnRH-a and GnRH-ant), 250 μg of recombinant hCG
(r-hCG; OvidrelW, Serono) was administered s.c. when at
least two follicles reached a mean diameter of ≥17 mm.
GnRH-a and GnRH-ant were administered until the day
of the hCG injection. Oocyte retrieval was performed by
transvaginal aspiration under ultrasound guidance 34 to
36 hours following the r-hCG injection.
Preparation of oocytes
The retrieved oocytes were incubated in culture medium
(P1; Irvine Scientific, Santa Ana, CA, USA) at 37°C and5.5% CO2 for 1 hour. Cumulus cells were removed by
exposing the oocytes to modified human tubal fluid
medium (mHTF; Irvine Scientific) containing 40 IU/ml
hyaluronidase (Irvine Scientific) for 30 sec, after which
coronal cells were manually removed using a stripper
buffer (Cook, Australia). The denuded oocytes were clas-
sified according to their level of maturation. Oocytes
with the first polar body, i.e., at the metaphase II (MII)
stage, were considered to be mature and were used for
the ICSI procedure.Oocyte morphology
Figure 1 shows normal oocyte and oocytes with cytoplas-
mic and extracytoplasmic dysmorphisms.
Two to four hours after the retrieval and before being
subjected to ICSI, MII oocytes from both groups were
morphologically analyzed under an inverted light micro-
scope (Nikon Eclipse TE 300 inverted microscope) by a
single operator blinded to subject identities. The oocytes
were classified as follows: [1,26-28].
– Normal: clear, homogenous cytoplasm with a
uniform texture, a round or ovoid first polar body
(PB) with a smooth surface, and a zona pellucida
and perivitelline space of normal size
– Cytoplasmic dysmorphism: the presence of vacuoles,
refractile bodies, granularity, and smooth
endoplasmic reticulum (SER) aggregations
– Extracytoplasmic dysmorphism: alterations of the
zona pellucida (thick and/or dark), perivitelline space
(large), polar body (fragmented, large, and/or
degenerated), and oocyte shape (irregular).
– Both cytoplasmic and extracytoplasmic
dysmorphisms.Statistical analysis
The statistical analysis was performed using software R,
version 2.13.0. The primary outcomes were the fre-
quency of oocyte dysmorphism in each group (agonist X
antagonist). First, statistical analysis was performed to
verify the homogeneity of the variables at the individual
level (age, body mass index (BMI), FSH) between the
GnRH-a and GnRH-ant groups. Then, the differences
between the groups at the level of the oocyte (presence
or absence of dysmorphism) were analyzed. The Mann–
Whitney test was used to verify the homogeneity of the
non-normal quantitative variables; Student’s t-test was
used for the normal quantitative variables. The chi-
squared test was used for the qualitative variables. To
determine whether either group had a significant effect
on the proportion of oocytes with dysmorphisms or if a
particular dysmorphism was more prevalent in any of
Figure 1 Oocytes with normal and abnormal morphology: (A) normal oocyte, (B) black arrow: smooth endoplasmic reticulum (SER)
aggregations; white arrow: abnormal polar body (C) large perivitelline space (D) abnormal oocyte shape (E) black arrow: central cytoplasmic
granulation; white arrow: abnormal polar body (F) cytoplasmic vacuoles (G) black arrow: refractile bodies; white arrow: smooth endoplasmic
reticulum (SER) aggregations (H) black arrow: dark thick zona pellucida and cytoplasm; white arrow: abnormal polar body.
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eralized estimating equations (GEE) method was used.
The variables describing morphological oocyte features
were presented as absolute and proportional frequencies.
The data from the logistic regression analyses were pre-
sented as the odds ratio (OR) and 95% confidence inter-
val (CI). The significance level was set at P< 0.05.
The sample size was calculated by a virtual comparison
between two proportions. Data from the literature show
that at least 20% of the MII oocytes have normal morph-
ology [29-31]. Thus, a sample size of 300 oocytes in eachgroup confers 80% power to detect an increase of 10% in
one of the groups with an alpha significance level of 0.05
(two-tailed).
Results
Basic demographic characteristics, such as maternal age,
BMI, duration of infertility, smoking, alcohol use, and in-
fertility etiology, were not significantly different (P> 0.05)
between the GnRH-a and GnRH-ant patient groups. The
distribution (P> 0.05) of the main characteristics of the
ovarian stimulation cycle observed for the GnRH-a and
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in Table 1.
A total of 681 oocytes were obtained: 330 oocytes from
the GnRH-a group and 351 from the GnRH-ant group.
Of these, 189 (27.8%) were morphologically normal, 220
(32.3%) had cytoplasmic dysmorphisms, 124 (18.2%) had
extracytoplasmic alterations, and 148 (21.7%) had both
dysmorphisms. The oocyte dysmorphisms were not sig-
nificantly different between the GnRH-a and GnRH-ant
groups (P> 0.05). Logistic regression analysis revealed
that the probability of finding a normal oocyte in the
GnRH-ant group was higher (OR:1.29, 95% CI: 0.76-
2.22) than in the GnRH-a group. However, the probabil-
ity of detecting an oocyte with cytoplasmic dysmorphism
in the GnRH-ant group was similar (OR:1.05, 95% CI:
0.62-1.81) to the probability of detecting such an oocyteTable 1 The basic demographic characteristics of the






Patients (n) 32 32
Age (years) 33.2 ± 3.0 32.5 ± 3.0 0.39
BMI (kg/m2) 23.5 ± 3.2 23.2 ± 3.0 0.48
Duration of
infertility (years)
4.4 ± 3.0 4.1 ± 3.0 0.33
Infertility 0.11
Primary 56.2% (18/32) 78.1% (25/32)
Secondary 43.8% (14/32) 21.9% (7/32)
Tobacco use (%) 3.1% (1/32) 0 (0/32) 0.31
Regular alcohol use 12.5% (4/32) 3.1% (1/32) 0.35
Etiology 0.59
Male factor 50% (16/32) 53.1% (17/32)
Idiopathic 34.4% (11/32) 21.9% (7/32)
Tubal factor 9.3% (3/32) 18.7% (6/32)
Male + Tuboperitoneal 6.3% (2/32) 6.3% (2/32)
Total dose FSH (UI) 2185.5 ± 617 1877.3 ± 817 0.09
Total dose LH (UI) 1094.5 ± 258 1026.5 ± 385 0.87
Time of stimulation
(days)











≥18 mm 4.1 ± 2.1 4.1 ± 1.8 0.65
Retrieved oocytes:
Total 12.5 ± 6.9 13.4 ± 7.0 0.57
Metaphase II stage 9.3 ± 5.9 9.8 ± 6.0 0.77
Metaphase I stage 1.3 ± 1.5 1.4 ± 1.4 0.22
Germinal vesicle stage 1.3 ± 2.5 0.9 ± 1.4 0.88
Implantation rate 29% (18/62) 27.4% (17/62) 1.00
Pregnancy rate 40.6% (13/32) 37.5% (12/32) 0.79in the GnRH-a group. However, the probability of detect-
ing an oocyte with extracytoplasmic dysmorphism or
both dysmorphisms in the GnRH-ant group was lower
(OR: 0.78, 95% CI: 0:38–1:59 and OR: 0.77. 95% CI: 0.38-
1.54, respectively) than for the GnRH-a group. Again,
these groups were not significantly different. These data
are summarized in Table 2.
It is possible that the oocytes exhibited more than one
change in morphology. When each dysmorphism was
analyzed, it was observed that alterations in polar body
shape (31.8%, 217/681) and the presence of diffuse cyto-
plasmic granulations (22.8%; 155/681), refractile bodies
(18.5%; 126/681) and central cytoplasmic granulations
(13.6%; 93/681) were the most common alterations.
Other morphological abnormalities were present in less
than 10% of the oocytes analyzed. Interestingly, cytoplas-
mic vacuoles (0.7%; 5/681) and changes in oocyte shape
(1.9%; 13/681) were not very common. The individual
incidences of oocyte dysmorphism obtained from the
GnRH-a and GnRH-ant groups were not significantly
different (P >0.05). These data are summarized in
Table 3.
Discussion
Oocyte quality is a major determinant of embryo quality
and the subsequent success of fertility treatment. Thus,
to improve the outcomes of assisted reproduction proce-
dures, it is important to identify non-invasive parameters
to evaluate oocyte quality. Among these, the examination
of egg phenotype using optical microscopy is the most
commonly used method.
A normal MII oocyte has a round shape, a single intact
polar body, a clear zona pellucida, a small perivitelline
space, and a transparent and smooth cytoplasm without
granules or inclusions [1,27,30,32,33]. However, most of the
oocytes collected after ovarian stimulation from infertile
patients or from some fertile donors have some type of dys-
morphism [27,28,30,32-37]. Various studies have demon-
strated the clinical importance of oocyte dysmorphism.
Indeed, specific intra- and extracellular morphological
changes in oocytes, such as granulations, cytoplasmic inclu-
sions, and abnormalities of the polar body, zona pellucida,
perivitelline space, and oocyte shape, have been shown to
be related to fertilization, cleavage, embryo development,
and clinical outcomes [1,26,29,30,33-47]. However, the
results are controversial. Other studies have reported the
prognostic value of oocyte morphology with respect to the
IVF results, depending on the dysmorphism and results
analyzed [27,39,46-51]. The variance in results can be
explained by the use of different morphological criteria
and/or a lack of standardization in the assessment of
oocytes. Additionally, the factors involved in the induction
of the morphological changes may have contributed to this
variability.
Table 2 Comparison of the overall prevalence of oocyte dysmorphisms in the GnRH agonist and GnRH antagonist
groups
Oocyte characteristics Total Group P Odds ratio (95% CI)
Agonist Antagonist
n: 681 n: 330 n: 351
Oocytes: 0.34 1.29 (0.75–2.22)
Normal 27.8% (189) 25.8% (85) 29.6% (104)
Dysmorphic 72.2% (492) 74.2% (245) 70.4% (247)
Cytoplasmic dysmorphism 32.3% (220) 32.1% (106) 32.5% (114) 0.84 1.05 (0.61–1.80)
Extracytoplasmic dysmorphism 18.2% (124) 19.4% (64) 17.1% (60) 0.48 0.78 (0.37–1.59)
Cytoplasmic + extracytoplasmic dysmorphism 21.7% (148) 22.7% (75) 20.8% (73) 0.45 0.77(0.38–1.54)
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sperm, it needs to go through a series of events that lead to
both nuclear and cytoplasmic maturity. However, these
events may occur independently [1,46,52]. After denuda-
tion, it is possible to verify the presence of the first polar
body, which proves the maturity of the oocyte nucleus.
However, the assessment of cytoplasmic maturation is not
well established. Some authors correlate this cytoplasmic
maturity with the lack of cytoplasmic inclusions. In other
words, a mature oocyte is one without granulation, with
vacuoles, and with uniform and clear cytoplasm [53].
Therefore, the presence of cytoplasmic inclusions could
represent cytoplasmic immaturity, which would affect
fertilization and embryonic development. Although imma-
ture oocytes can be fertilized, the subsequent course of em-
bryonic development is abnormal [53]. Extra-cytoplasmic
alterations may also be related to the maturity of the oo-
cyte. An increase in the perivitelline space could be related
to the premature exocytosis of cortical granules, suggesting
a post-mature cytoplasm [54]. The presence of granulation
in the perivitelline space is likely to be a physiologic
phenomenon related to oocyte maturity, mainly because
the incidence of this change was significantly moreTable 3 Comparison of the prevalence of specific dysmorphis
Oocyte characteristics Total Grou
Agon
n:681 n:33
Cytoplasmic dysmorphism (presence of)
Diffuse granulation 22.8% (155) 25.2%
Central cytoplasmic granulation 13.6% (93) 12.1%
Refractile bodies 18.5% (126) 20.3%
SER aggregations 2.3% (16) 1.8%
Vacuoles 0.7% (5) 0.9%
Extracytoplasmic (alterations)
Polar body shape 31.3%(213) 30.9%
Perivitelline space 6.8% (46) 8.2%
Zona pellucida 3.4% (23) 4.8%
Oocyte shape 1.9% (13) 1.1%
* oocytes could present more than 1 dysmorphism.frequent in oocytes at stage MII (mature oocytes) as com-
pared with immature oocytes. The control of meiotic re-
sumption in mammalian oocytes depends on a network of
extracellular and intracellular molecular interactions [55-
58]. Understanding the regulatory role of such interactions
in oocyte maturation is important for the analysis of oocyte
phenotype. Some mechanisms that regulate GnRH or go-
nadotropin-regulated oocyte quality/maturity may regulate
gamete morphology.
GnRH receptors are expressed in the human ovary, but
the action of GnRH analogues on oocyte morphology and
quality remains controversial. In the present study, no sig-
nificant difference was observed between the incidence of
oocyte dysmorphisms and the type of analogue used for pi-
tuitary suppression during IVF. In contrast to our findings,
Murber et al. [4] found a significantly higher incidence of
cytoplasmic changes in the GnRH-ant group than in the
GnRH-a group (62.1% and 49.9%, respectively; P< 0.01). In
another study in which different stimulation protocols were
evaluated, Otsuki et al. [26] found that SER aggregations
were more common in short GnRH-a protocols as com-
pared with long-term protocols. However, differences
in the study design [4,26], in the populations, and inms in the GnRH agonist and GnRH antagonist groups
p P Odds ratio (95% CI)
ist Antagonist
0 n:351
(83) 20.5% (72) 0.17 0.95 (0.44–2.06)
(40) 15.1% (53) 0.32 1.06 (0.48–2.44)
(67) 16.8% (59) 0.27 0.88 (0.32–2.43)
(6) 2.8% (10) 0.45 1.41 (0.25–7.85)
(3) 0.6% (2) 0.93 0.66 (0.07–6.37)
(102) 31.6%(111) 0.90 0.78 (0.38–1.61)
(27) 5.4% (19) 0.19 0.66 (0.28–1.52)
(16) 2.0% (7) 0.06 0.40 (0.15–1.06)
(7) 1.7% (6) 0.78 0.79 (0.26–2.35)
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findings. Our findings are in agreement with those of
Rienzi et al. [1], who analyzed 1,191 MII oocytes. Their
retrospective study included three distinct protocols
for controlled ovarian hyperstimulation, a long-term
GnRH-a protocol (268 cycles), a GnRH-ant protocol
(142 cycles), and a natural cycle with minimal stimula-
tion (106 cycles). No correlation was found between
the protocol used for ovarian hyperstimulation and oo-
cyte morphology [1].
Pharmacological doses of gonadotropins in stimulated
cycles create a hormonal environment that induces the
growth of a cohort of follicles that would otherwise degen-
erate under in vivo conditions. Thus, the type of gonado-
tropin used is also a factor that likely influences the quality
of the oocyte. In our study, regardless of the analogue used
(agonist or antagonist), all cycles were stimulated by r-LH
in addition to r-FSH, and this factor has yet to be analyzed.
Some studies have reported the beneficial effects of using
r-LH on ovarian physiology and clinical outcomes [59,60].
In addition, Ruvolo et al. [61] suggested that supplementa-
tion with r-LH improves the chromatin quality of cumulus
cells and protects them from apoptosis, possibly acting
directly on granulosa cells or via a paracrine effect. These
authors suggested that by maintaining the physiological
function of the cumulus cells over time, the nuclear and
cytoplasmic maturation of the oocyte would also be main-
tained, which would improve the quality of the oocytes at
the time of retrieval. Detti et al. [62] speculated that sup-
plementation with LH and FSH may have had a positive
effect on oocyte quality. Acevedo et al. [63] randomly
assigned 20 oocyte donors to ovarian stimulation protocols
using GnRH-ant alone or GnRH-ant with recombinant
LH and observed that LH activity supplementation
improved oocyte quality. Thus, it can be hypothesized that
the r-LH used in our study had a positive effect on oocyte
morphology, which compensated for any possible deleteri-
ous effect of GnRH-a or GnRH-ant on ovarian physiology.
In fact, Hernadez et al. [64] reported that a GnRH-ant
inhibited the cell cycle by decreasing the synthesis of
growth factors and thereby compromised the mitotic
program of follicles and oocyte quality. However, this
hypothesis needs to be tested with additional controlled
trials. It should be noted that in our study, the overall inci-
dences of oocyte dysmorphism in both the GnRH-a and
GnRH-ant groups were similar to those reported in the lit-
erature, suggesting that any beneficial effects were asso-
ciated with the protocols used for ovarian stimulation. In
addition, Rashidi et al. [3] performed a randomized study
comparing human menopausal gonadotropin (HMG) with
r-FSH and did not find differences in the morphology of
the MII oocytes retrieved.
Although there are several studies that have evaluated
the clinical protocols of ovarian stimulation, very little isknown regarding the correlation between these protocols
and oocyte morphology. The majority of published studies
that focus on oocyte morphology have examined its associ-
ation with the results of IVF and not with the ovarian
stimulation protocol [33,34,38,40,47,49]. In a recent meta-
analysis [46], the oocyte dysmorphisms that were nega-
tively correlated with fertilization rate, i.e., a lower chance
of the fertilization of an oocyte, included changes in the
first polar body, an increase in the perivitelline space, and
the presence of refractile bodies and cytoplasmic vacuoles.
The present study found that 72.2% of oocytes had at least
one morphologic change, which is consistent with the 60-
80% values reported by Figueira et al. [52] (60.2%); Rienzi
et al. [1] and Yakin et al. [29] (84%); Kahraman et al. [39]
(65.8%); Aguiar et al. [65] (67.3%); Balaban et al. [32]
(63.1%); and De Sutter et al. [27] (63.5%). Among the dys-
morphisms, cytoplasmic changes were the most common
(32.3%), followed by the simultaneous occurrence of cyto-
plasmic and extracytoplasmic changes (21.7%). Strictly
extracytoplasmic changes were the least common (18.2%).
Conflicting data were reported by Balaban et al. [32], who
showed a higher percentage of extracytoplasmic changes,
followed by extra- and cytoplasmic changes and then fi-
nally by cytoplasmic changes. Mikkelsen and Lindenberg
[54] also reported a higher incidence of extracytoplasmic
changes followed by a smaller increase in the frequency of
cytoplasmic changes.
When the dysmorphisms were evaluated individually, the
most common cytoplasmic change found was cytoplasmic
granularity (diffuse and central), followed by refractile bod-
ies, SER aggregations and, finally, the presence of vacuoles.
Balaban et al. [32] reported a different order of prevalence
(in decreasing order of frequency): dark cytoplasm, refractile
bodies, and granular cytoplasm. Rienzi et al. [1] reported an
order of prevalence similar to ours: cytoplasmic granularity
was the most common, followed by refractile bodies,
vacuoles, and SER; the only difference was in the observed
frequencies of vacuoles and SER. In our study, the most
prevalent changes in the extracytoplasmic dysmorphisms
were related to the first polar body, followed by changes in
the perivitelline space, zona pellucida, and oocyte shape, as
reported by Rienzi et al. [1]. However, Balaban et al. [32]
showed that the most frequent extracytoplasmic alterations
were an increase in the perivitelline space, followed by a
dark pellucida area and shape abnormalities. Aguiar et al.
[48] showed that 42.8% of oocytes had multiple changes,
40% had cytoplasmic inclusions, 14.3% exhibited fragmenta-
tion of the polar body, and 2.9% displayed enlargements of
the perivitelline space.
Some limitations of our study should be noted. The
population of 64 patients is small (32 patients per group),
despite the inclusion of over 300 eggs per group. This low
number may have influenced the results. However, a study
[1] involving a larger number of patients did not reveal
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the ovarian stimulation protocol used. Our study is rando-
mized in terms of the patient population, but the statistical
analysis is calculated based on the number of eggs. If the
patient population is randomized, it is fair to assume that
the egg quality is similar up until stimulation and that any
changes observed will be due to the stimulation itself.
While randomization could compensate for any bias in
terms of known and unknown patient-related factors that
influence egg quality, certain factors will tend to be over-
represented by those patients who provide more eggs (on
average each patient provided 10 eggs). However, it should
be noted that, again, a study [1] that limited the number of
oocytes analyzed per patient did not reveal significant dif-
ferences in oocyte morphology in relation to the ovarian
stimulation protocol used.
Conclusions
Our randomized data indicate that in terms of the quality
of oocyte morphology, there is no difference related to the
use of a multi-dose antagonist protocol or a long-term
agonist protocol. If a GnRH analogue used for pituitary sup-
pression in IVF cycles influences the prevalence of various
oocyte dysmorphisms, there does not appear to be a differ-
ence between the use of an agonist or an antagonist. To the
best of our knowledge, this is the first randomized trial that
has analyzed this association. A future randomized con-
trolled trial with a larger sample size would be helpful to
corroborate these findings.
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